Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Aptinyx Inc. (NASDAQ:APTX), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of the two firms.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aimmune Therapeutics Inc. N/A 0.00 194.92M -3.00 0.00 Aptinyx Inc. 6.72M 27.02 46.41M -1.42 0.00 Demonstrates Aimmune Therapeutics Inc. and Aptinyx Inc. earnings per share, top-line revenue and valuation.
Table 2 provides us Aimmune Therapeutics Inc. and Aptinyx Inc.’s return on assets, return on equity and net margins. Net Margins Return on Equity Return on Assets Aimmune Therapeutics Inc. 0.00% -74.8% -65.9% Liquidity
Aimmune Therapeutics Inc.’s Current Ratio is 7 while its Quick Ratio is 7. On the competitive side is, Aptinyx Inc. which has a 21.8 Current Ratio and a 21.8 Quick Ratio. Aptinyx Inc. is better positioned to pay off short and long-term obligations compared to Aimmune Therapeutics Inc.
Institutional & Insider Ownership
Aimmune Therapeutics Inc. and Aptinyx Inc. has shares held by institutional investors as follows: 84.8% and 76%. About 0.7% of Aimmune Therapeutics Inc.’s share are held by insiders. Insiders Comparatively, held 3.9% of Aptinyx Inc. shares.
In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Aimmune Therapeutics Inc. -2.48% -28.01% -14.98% -25.19% -32.08% -38.76% Aptinyx Inc. -6.03% -19.01% -34.47% 0% 0% 3.32% For the past year Aimmune Therapeutics Inc. had bearish trend while Aptinyx Inc. had bullish trend.
On 8 of the 9 factors Aptinyx Inc. beats Aimmune Therapeutics Inc.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Click here to view original web page at Reviewing Aimmune Therapeutics Inc. (AIMT)’s and Aptinyx Inc. (NASDAQ:APTX)’s results